Gabelli Healthcare & WellnessRx Trust (GRX) raised its quarterly payout after 14 consecutive years of unbroken distributions.

GRX’s 7% yield relies heavily on return of capital (60%) rather than underlying dividend income (2%).

Healthcare sector growth reached 8.9% of U.S. GDP in 2025, underpinning the fund’s distribution sustainability.

The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE.

Income investors shopping the healthcare aisle often land on Gabelli Healthcare & WellnessRx Trust (NYSE:GRX), a closed-end fund managed by Gabelli Funds that has quietly paid quarterly distributions for more than 14 consecutive years. The fund just raised its payout, insiders keep buying, and the underlying sector is one of the most stable slices of U.S. GDP. The question for investors is whether the roughly 7% annualized yield is as durable as the streak suggests.

GRX is a leveraged, diversified closed-end fund with $231 million in net assets and an objective of long-term capital growth across healthcare and wellness. Income reaches shareholders through a managed distribution policy rather than a simple pass-through of dividends.

The analyst who called NVIDIA in 2010 just named his top 10 stocks. Get them here FREE.

The 2026 distribution mix tells the real story: 2% from net investment income, 38% from net capital gains, and 60% as return of capital on a book basis. In plain terms, only a sliver of the $0.17 quarterly check comes from dividends the underlying stocks pay. The rest is funded by realized gains from Gabelli’s trading and, heavily, by return of capital. ROC often reflects unrealized appreciation being distributed tax-efficiently, so the payout ultimately tracks the portfolio’s total return rather than the underlying dividend stream.

The portfolio skews to healthcare heavyweights and consumer staples with a wellness bent. Sector weights break down as follows:

21% Health Care Providers and Services, 20% Pharmaceuticals, 18% Health Care Equipment, 18% Food, and 8% Food and Staples Retailing

roughly 5% in cash

Top holdings include AbbVie, Tenet Healthcare, BellRing Brands, Johnson & Johnson, Cigna, UnitedHealth, Elevance, and Post Holdings, a roster built more for cash-generative durability than yield chasing.

That matters for distribution safety. Healthcare has logged positive growth every quarter since 2023, with 2025 Q4 value added of $2.78 trillion representing 8.9% of U.S. GDP. The underlying businesses Gabelli owns throw off steady cash, which gives management realized gains to harvest and distribute.

Because GRX uses leverage, the Fed matters as much as the portfolio. The Fed funds upper bound sits at 3.75%, down 75 basis points over the past year. Cheaper borrowing widens the spread between what GRX pays on its preferred shares and what the assets earn, directly supporting distribution capacity. The 10-year Treasury near 4.3% keeps competition for income dollars real, but the trajectory favors the fund.

Insider activity reinforces the stability thesis:

Mario Gabelli added shares in December 2025 and January 2026, lifting his combined stake above 560,000 shares.

Saba Capital, a known activist in CEFs, has accumulated more than 2.1 million shares.

The April 2026 hike from $0.15 to $0.17 per quarter followed 12 straight quarters at $0.15.

Total return context tempers the enthusiasm. Shares trade near $9, down about 4% year-to-date and roughly 4% lower over five years, though the ten-year gain sits near 61% before distributions. Investors are collecting real income, but NAV erosion from the ROC-heavy payout is a genuine headwind over long holding periods.

The distribution looks safe in the near term. Leverage is getting cheaper, the portfolio sits in a defensive sector with steady fundamentals, insiders are buying, and the fund just raised the payout after more than a decade of unbroken quarterly checks. The caveat is structural: with 60% of 2026 distributions classified as return of capital and a 2.5% expense ratio, GRX suits investors who want healthcare income today and accept modest price appreciation. Those seeking capital growth alongside yield will find cleaner options elsewhere.

This analyst’s 2025 picks are up 106% on average. He just named his top 10 stocks to buy in 2026. Get them here FREE.